Finding. Lose the same grams two ways and the marrow disagrees. Krah, Chaix, Rutter and colleagues match tirzepatide to caloric restriction in obese mice. Restriction causes cytopenias and turns down hematopoietic-stem-and-progenitor nutrient sensing, cycling, and oxidative-phosphorylation genes. Tirzepatide keeps blood lineages, softens those progenitor hits, and instead carves away classical Ly6C-high CCR2-positive monocytes. As cells mature, the drug further suppresses OXPHOS and shifts the spectrum off that monocyte. Stop the drug, regain the weight, and those monocytes come home.
Score 77. OXPHOS as the modality split, a reversible monocyte handle. Confidence is medium: gene sets, mice.
What to do with it If you score GLP-1/GIP immunology, this is the HSPC-OXPHOS versus CR paper. Do not equate diet and dual agonist in marrow.